Type 2 Diabetes, Dyslipidemia
Conditions
Interventions
Administration of Cholestimide 3g/day add on to statin for the first 24 weeks, then withdrawal of Cholestimide for the next 24 weeks
Administration of statin for the first 24 weeks, then add Cholestim
Sponsors
Tokyo Women's Medical University, Diabetes Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients whose body mass index(BMI) is above 25, Visceral fat area is above 100cm2, andHbA1c(NGSP) is above 6.5% Patients who have dyslipidemia and administered by Atorvastatin , Pitavastatin or Rosuvastation at least for 2 months, and LDL-cholesterol is above 90 mg/dl
Exclusion criteria
Exclusion criteria: Patients with complete biliary obstruction Patients with hypersensitivity to cholestimide or past history of ileus. Patients with poor control of constipation Patients who take warfarin, tetracycline, Phenobarbital, thyroid gland preparation, digitalis Patients with unstable proliferative diabetic retinopathy Patients whose stage of diabetic nephropathy is above stage 4 Patients who have active infection or are under treatment of malignancy Patients who have macroangiopathy Patients who are considered to be inadequate to participate in this study.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| 1. Resting energy expenditure, Respiratory quotient 2. HbA1c, blood glucose, Insulin secretion 3.lipid metabolism 4.oxidative stress | — |
Primary
| Measure | Time frame |
|---|---|
| Visceral fat area | — |
Countries
Japan
Contacts
Public ContactRisa Ide
Tokyo Women's Medical University Diabetes Center
Outcome results
None listed